CLINICAL TRIALS WITH SOLID INTRACRANIAL TUMORS &NEOPLASTIC MENINGITIS

$313,976P50FY2002NSNIH

Duke University, Durham NC

Investigators

Linked publications & trials

Paper 26759007 Paper 25843513 Paper 25762141 Paper 25312738 Paper 24939611 Paper 24776093 Paper 24722266 Paper 24722048 Paper 24570975 Paper 24460937 Paper 24373972 Paper 24075405 Paper 24054399 Paper 23982483 Paper 23924792 Paper 23857604 Paper 23837761 Paper 23806556 Paper 23634286 Paper 23591978 Paper 23581583 Paper 23530248 Paper 23527092 Paper 23280793 Paper 23248284 Paper 23159039 Paper 23132717 Paper 23115013 Paper 23052252 Paper 23037712 Paper 22964392 Paper 22899282 Paper 22869205 Paper 22727691 Paper 22535433 Paper 22407177 Paper 22400035 Paper 22383993 Paper 22371319 Paper 22346349 Paper 22241217 Paper 22202151 Paper 22201707 Paper 21997879 Paper 21986722 Paper 21961046 Paper 21958852 Paper 21938530 Paper 21817013 Paper 21809989 Paper 21744079 Paper 21729780 Paper 21719641 Paper 21590689 Paper 21590380 Paper 21531816 Paper 21466382 Paper 21464146 Paper 21430586 Paper 21291403 Paper 21243098 Paper 21233176 Paper 21220131 Paper 21149254 Paper 21149252 Paper 21119888 Paper 21087515 Paper 20921459 Paper 20870149 Paper 20853132 Paper 20824708 Paper 20809959 Paper 20718706 Paper 20716591 Paper 20472715 Paper 20443129 Paper 20424975 Paper 20414475 Paper 20210709 Paper 20150978 Paper 20030624 Paper 20025498 Paper 19944071 Paper 19937796 Paper 19920819 Paper 19920201 Paper 19825799 Paper 19818334 Paper 19785068 Paper 19647173 Paper 19647172 Paper 19562254 Paper 19533023 Paper 19466671 Paper 19426505 Paper 19402172 Paper 19289491 Paper 19261750 Paper 19248046 Paper 19228619

Abstract

DESCRIPTION: Given the toxicity and poor survival results after current treatment modalities, regional therapy using monoclonal antibody-based strategies and alkylators may have clinical potential. The PI proposes to define the MTD and therapeutic benefits of 9 different approaches, 6 for solid intracranial tumors and 3 for neoplastic meningitis. For solid tumors, 4 approaches involved intratumoral or intracystic infusions: (1) 131-I-81C6, (2) 211-Att-ch81C6, (3) ch81C6-streptavidin followed by 211-At-biotin or 131-I-biotin, (4) 211-At or I-131 conjugated alpha-EGFRvIII/ fragments; and 2 approaches only intratumoral infusions: (1) MRI (a-EGFRvIII-scFv-pseudomonas toxin), and (2) TP38 (TGFa-pseudomonas toxin). For neoplastic meningitis, two treatment studies were chemotherapy based: melphalan and camptothecin analogues and the rest utilized 131-I-Mel-14, 131-I-81C6, and other anti-medullobastoma antibodies and genetic variants.

View original record on NIH RePORTER →